

# Megan S Lim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2593381/publications.pdf>

Version: 2024-02-01

44  
papers

2,721  
citations

394421

19  
h-index

302126

39  
g-index

44  
all docs

44  
docs citations

44  
times ranked

2952  
citing authors

#	ARTICLE	IF	CITATIONS
1	Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus. <i>Archives of Pathology and Laboratory Medicine</i> , 2023, 147, 79-86.	2.5	1
2	Transcriptome and unique cytokine microenvironment of Castleman disease. <i>Modern Pathology</i> , 2022, 35, 451-461.	5.5	10
3	Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review. <i>Hematological Oncology</i> , 2022, 40, 191-201.	1.7	6
4	Significance of <i>RUNX1</i> mutation in <i>BCR-ABL1</i> positive acute myeloid leukemia â€” a diagnostic dilemma in a young woman with persistent bleeding. <i>Leukemia and Lymphoma</i> , 2022, , 1-5.	1.3	0
5	The disease course of Castleman disease patients with fatal outcomes in the <sc>ACCELERATE</sc> registry. <i>British Journal of Haematology</i> , 2022, , .	2.5	2
6	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. <i>Leukemia</i> , 2022, 36, 1720-1748.	7.2	1,023
7	Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1. <i>Blood</i> , 2021, 137, 3595-3603.	1.4	40
8	Characterizing Mortality Associated with Idiopathic Multicentric Castleman Disease. <i>Blood</i> , 2021, 138, 1623-1623.	1.4	2
9	Characterization of Castleman Disease Reveals Patients with Oligocentric Adenopathy and Clinicopathologic Characteristics Similar to Unicentric Castleman Disease. <i>Blood</i> , 2021, 138, 1622-1622.	1.4	0
10	A Novel FBXO45-Gef-H1 Axis Controls Oncogenic Signaling in B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 711-711.	1.4	1
11	Pathology and genetics of anaplastic large cell lymphoma. <i>Seminars in Diagnostic Pathology</i> , 2020, 37, 57-71.	1.5	31
12	The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma. <i>Oncogene</i> , 2020, 39, 2103-2117.	5.9	9
13	Mastermind: A Comprehensive Genomic Association Search Engine for Empirical Evidence Curation and Genetic Variant Interpretation. <i>Frontiers in Genetics</i> , 2020, 11, 577152.	2.3	46
14	Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. <i>American Journal of Hematology</i> , 2020, 95, 1553-1561.	4.1	18
15	International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. <i>Blood Advances</i> , 2020, 4, 6039-6050.	5.2	94
16	A Novel Approach for the Treatment of T Cell Malignancies: Targeting T Cell Receptor $\hat{V}\hat{I}^2$ Families. <i>Vaccines</i> , 2020, 8, 631.	4.4	2
17	Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Childrenâ€™s Oncology Group AALL0434. <i>Journal of Clinical Oncology</i> , 2020, 38, 3062-3070.	1.6	42
18	Discovery of Novel Recurrent Mutations and Clinically Meaningful Subgroups in Nodal Marginal Zone Lymphoma. <i>Cancers</i> , 2020, 12, 1669.	3.7	2

#	ARTICLE	IF	CITATIONS
19	ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder. <i>Cell Reports Medicine</i> , 2020, 1, 100158.	6.5	18
20	Mass spectrometry and proteomics in hematology. <i>Seminars in Hematology</i> , 2019, 56, 52-57.	3.4	11
21	Molecular Genetics in the Diagnosis and Biology of Lymphoid Neoplasms. <i>American Journal of Clinical Pathology</i> , 2019, 152, 277-301.	0.7	6
22	Immunophenotypic, cytotoxic, proteomic and genomic characterization of human cord blood vs. peripheral blood CD56 <sup>+</sup> Dim <sup>-</sup> NK cells. <i>Innate Immunity</i> , 2019, 25, 294-304.	2.4	8
23	Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation, <i>in-vitro</i> proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. <i>Oncolmmunology</i> , 2019, 8, e1512455.	4.6	17
24	Epigenetic Modulation of CD48 By NPM-ALK Promotes Immune Evasion in ALK+ ALCL. <i>Blood</i> , 2019, 134, 1510-1510.	1.4	8
25	Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain. <i>Blood</i> , 2019, 134, 1540-1540.	1.4	3
26	New Insights into Lymphoma Pathogenesis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2018, 13, 193-217.	22.4	27
27	Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma. <i>Oncotarget</i> , 2018, 9, 21820-21830.	1.8	24
28	Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond. <i>Cancers</i> , 2018, 10, 99.	3.7	59
29	Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenase-positive cells in primary diffuse large B-cell lymphoma of the central nervous system. <i>Oncolmmunology</i> , 2018, 7, e1442164.	4.6	34
30	Epiproteomic Landscape and Histone Code of Cutaneous T-Cell Lymphoma/S�zary Syndrome. <i>Blood</i> , 2018, 132, 780-780.	1.4	1
31	International, evidence-based consensus diagnostic criteria for HHV-8�negative/idiopathic multicentric Castleman disease. <i>Blood</i> , 2017, 129, 1646-1657.	1.4	381
32	Pyrimidine tract-binding protein 1 mediates pyruvate kinase M2-dependent phosphorylation of signal transducer and activator of transcription 3 and oncogenesis in anaplastic large cell lymphoma. <i>Laboratory Investigation</i> , 2017, 97, 962-970.	3.7	21
33	Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report. <i>British Journal of Haematology</i> , 2017, 177, 601-611.	2.5	15
34	Functional proteogenomics reveals biomarkers and therapeutic targets in lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 6581-6586.	7.1	32
35	T-cell Receptor Signaling Activates an ITK/NF-�B/GATA-3 axis in T-cell Lymphomas Facilitating Resistance to Chemotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 2506-2515.	7.0	49
36	Target and Agent Prioritization for the Children's Oncology Group's National Cancer Institute Pediatric MATCH Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	85

#	ARTICLE	IF	CITATIONS
37	Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3215-3221.	1.6	315
38	A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment. <i>Oncotarget</i> , 2017, 8, 113895-113909.	1.8	15
39	Activating <i>KRAS</i> mutations are characteristic of oncocytic sinonasal papilloma and associated sinonasal squamous cell carcinoma. <i>Journal of Pathology</i> , 2016, 239, 394-398.	4.5	55
40	Mature and <i>NK</i> cell non-Hodgkin lymphoma in children and young adolescents. <i>British Journal of Haematology</i> , 2016, 173, 573-581.	2.5	23
41	Precision Medicine for Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 2829-2831.	7.0	7
42	Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in SÅzary syndrome. <i>Nature Communications</i> , 2015, 6, 8470.	12.8	177
43	N-Glycoproteomic Landscape of Human Lymphoid Cancers Reveals Novel Biomarkers and Potential Therapeutic Targets. <i>Blood</i> , 2015, 126, 697-697.	1.4	0
44	NPM-ALK Mediated Tyrosine Phosphorylation of ATP Citrate Lyase Regulates Lipid Metabolism and Promotes Oncogenesis of Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2015, 126, 465-465.	1.4	1